Skip to content

Association of Gut Microbiome and Lipid lowering Effect of Rosuvastatin

Association of Gut Microbiome and Lipid lowering Effect of Rosuvastatin

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ORC-17013212
Enrollment
Unknown
Registered
2017-11-02
Start date
2015-12-01
Completion date
Unknown
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Interventions

2:All patients received 10 mg/day of rosuvastatin for 4-8 weeks

Sponsors

Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 75 Years

Inclusion criteria

Inclusion criteria: The diagnosis of hyperlipidemia was based on the following inclusion criteria set by the Chinese society of Cardiology in 2007: serum LDL-C = 3.64mmol/L, high density lipoprotein (HDL) = 3.64mmol/L, TG = 1.70mmol/L, total cholesterol (TC) = 5.72mmol/L;Inclusion criteria: The diagnosis of hyperlipidemia was based on the following inclusion criteria set by the Chinese society of Cardiology in 2007: serum LDL-C = 3.64mmol/L, high density lipoprotein (HDL) = 3.64mmol/L, TG = 1.70mmol/L, total cholesterol (TC) = 5.72mmol/L;Inclusion criteria: The diagnosis of hyperlipidemia was based on the following inclusion criteria set by the Chinese society of Cardiology in 2007: serum LDL-C = 3.64mmol/L, high density lipoprotein (HDL) = 3.64mmol/L, TG = 1.70mmol/L, total cholesterol (TC) = 5.72mmol/L;Inclusion criteria: The diagnosis of hyperlipidemia was based on the following inclusion criteria set by the Chinese society of Cardiology in 2007: serum LDL-C = 3.64mmol/L, high density lipoprotein (HDL) = 3.64mmol/L, TG = 1.70mmol/L, total cholesterol (TC) = 5.72mmol/L;Inclusion criteria: The diagnosis of hyperlipidemia was based on the following inclusion criteria set by the Chinese society of Cardiology in 2007: serum LDL-C = 3.64mmol/L, high density lipoprotein (HDL) = 3.64mmol/L, TG = 1.70mmol/L, total cholesterol (TC) = 5.72mmol/L

Exclusion criteria

Exclusion criteria: Patients were excluded if they had at least one of the following conditions: 1) a history of antibiotic application (within 3 months); 2) long-term use of steroid hormone, thyroid hormone, contraceptive drugs and drugs that affect lipid parameters of serum; 3) active liver and kidney diseases; 4) uncontrolled hypothyroidism; 5) adrenocortical hyperfunction; 6) acute and chronic disorders of the digestive system.;Exclusion criteria: Patients were excluded if they had at least one of the following conditions: 1) a history of antibiotic application (within 3 months); 2) long-term use of steroid hormone, thyroid hormone, contraceptive drugs and drugs that affect lipid parameters of serum; 3) active liver and kidney diseases; 4) uncontrolled hypothyroidism; 5) adrenocortical hyperfunction; 6) acute and chronic disorders of the digestive system.;Exclusion criteria: Patients were excluded if they had at least one of the following conditions: 1) a history of antibiotic application (within 3 months); 2) long-term use of steroid hormone, thyroid hormone, contraceptive drugs and drugs that affect lipid parameters of serum; 3) active liver and kidney diseases; 4) uncontrolled hypothyroidism; 5) adrenocortical hyperfunction; 6) acute and chronic disorders of the digestive system.;Exclusion criteria: Patients were excluded if they had at least one of the following conditions: 1) a history of antibiotic application (within 3 months); 2) long-term use of steroid hormone, thyroid hormone, contraceptive drugs and drugs that affect lipid parameters of serum; 3) active liver and kidney diseases; 4) uncontrolled hypothyroidism; 5) adrenocortical hyperfunction; 6) acute and chronic disorders of the digestive system.;Exclusion criteria: Patients were excluded if they had at least one of the following conditions: 1) a history of antibiotic application (within 3 months); 2) long-term use of steroid hormone, thyroid hormone, contraceptive drugs and drugs that affect lipid parameters of serum; 3) active liver and kidney diseases; 4) uncontrolled hypothyroidism; 5) adrenocortical hyperfunction; 6) acute and chronic disorders of the digestive system.

Design outcomes

Primary

MeasureTime frame
Bacterial DNA from the faeces;triglyceride;total cholesterol;high density lipoprotein;low density lipoprotein cholesterol;

Countries

China

Contacts

Public ContactLi Tang;Li Tang;Li Tang;Li Tang;Li Tang ;;;;

Dalian Medical University;Dalian Medical University;Dalian Medical University;Dalian Medical University;Dalian Medical University

tangli_2015cn@sina.com;tangli_2015cn@sina.com;tangli_2015cn@sina.com;tangli_2015cn@sina.com;tangli_2015cn@sina.com+86 0411-86110305;+86 0411-86110305;+86 0411-86110305;+86 0411-86110305;+86 0411-86110305

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 24, 2026